Provectus Pharmaceuticals Inc.

• Public
• US

Dow Jones Description

Provectus, and its five wholly owned subsidiaries: o Xantech Pharmaceuticals, Inc. o Pure-ific Corporation o Provectus Biotech, Inc. o Provectus Devicetech, Inc. o Provectus Pharmatech, Inc. (which we refer to as our subsidiaries) develop, license and market and plan to sell products in three sectors of the healthcare industry: o Over-the-counter products, which we refer to in this report as "OTC products;" o Prescription drugs; and o Medical device systems We manage Provectus and our subsidiaries on an integrated basis and when we refer to "we" or "us" or "the Company" in this Annual Report on Form 10-KSB, we refer to all six corporations considered as a single unit. Our principal executive offices are located at 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931, telephone 865/769-4011. Through discovery and use of state-of-the-art scientific and medical technologies, the founders of our pharmaceutical business have developed a portfolio of patented, patentable, and proprietary technologies that support multiple products in the prescription drug, medical device and OTC products categories (including patented technologies for: (a) treatment of cancer; (b) novel therapeutic medical devices; (c) enhancing contrast in medical imaging; (d) improving signal processing during biomedical imaging; and (e) enhancing production of biotechnology products).

Number of Employees 7

Contact Information

Peer Companies

• Johnson & Johnson
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Novartis AG
• AstraZeneca Plc.
• All Companies